세계 기저세포암 치료 시장 – 2023-2030

Market Overview
The global basal cell carcinoma treatment market size was valued at US$ XX million in 2023 and is estimated to reach US$ XX million by 2030, growing at a CAGR of 9.4% during the forecast period (2023-2030).
Basal cell carcinoma (BCC) is a type of skin cancer. Basal cells, a type of skin cell that creates new skin cells as old ones degenerate, are where basal cell cancer starts. Although it can take numerous forms, basal cell carcinoma frequently manifests as a small, slightly translucent lump on the skin. The skin on the head and neck, as well as other sun-exposed locations, tends to develop basal cell carcinoma more frequently than other skin types.
Market Dynamics
The major factors driving the global basal cell carcinoma treatment market are the market is predicted to grow as skin cancers become more common and product approval for basal cell carcinoma therapy. People are becoming more mindful of their health, which helps the market grow.
Product approval for basal cell carcinoma therapy is expected to drive the market’s growth.
The frequency of keratinocyte tumors, commonly known as non-melanoma skin malignancies, is rising worldwide, with basal cell carcinoma and squamous cell carcinoma being the most prevalent types. Even though surgery is the preferred course of action for both cancers, some cases can proceed to an advanced or metastatic stage, necessitating targeted therapy. The hedgehog signaling system heavily influences basal cell carcinoma, and its suppression is the key to new therapeutic approaches for both locally progressed and metastatic basal cell carcinoma. Preclinical and clinical research using already FDA-approved medications point to new applications for BCC chemoprevention and therapy. Additionally, novel chemical compounds that block the Hh pathway exhibit promise and may offer a nonsurgical treatment for this most prevalent malignancy when combined with other medications.
Then, the major players in the market are concentrating on getting their products approved for the treatment of basal cell carcinoma, which is anticipated to propel the growth of the global basal cell carcinoma market during the forecast period. For instance, in June 2021, The European Commission (EC) authorized Sanofi, a French multinational pharmaceutical company with its headquarters in Paris, to use Regeneron's PD-1 inhibitor Libtayo (cemiplimab) to treat adults with locally advanced or metastatic basal cell carcinoma (BCC) who have progressed on or become intolerable to a hedgehog pathway inhibitor (HHI).
Lack of skilled experts is expected to hamper the market’s growth.
The development of the global basal cell carcinoma treatment market over the forecast period may be constrained by a need for more skilled experts who are ignorant of the available treatment options for this illness.
COVID-19 Impact Analysis
The global market for basal cell carcinoma therapeutics was adversely affected by the covid-19. The increase in cancer cases had a negative impact on the number of diagnoses and thus hindered global Therapy. The discovery of new cases decreased, especially during the early stages of the pandemic, due to the healthcare systems' strong concentration on controlling the COVID-19 pandemic, a considerable drop in the number of diagnostic procedures, and a dip in procedures such as skin lesion biopsies.
Additionally, the COVID-19 pandemic is providing serious challenges for industry players in the global basal cell carcinoma market on a number of fronts. One of the biggest problems caused by transportation irregularities is the availability of raw materials required to produce pharmaceutical formulations. Additionally, due of an increase in patients with COVID-19 and other life-threatening disorders, distributors are witnessing unpredictable demand for their products from retailers.
Segment Analysis
The surgical excision segment is expected to grow at the fastest CAGR during the forecast period (2022-2029)
The treatment segment is the highest market holder in the global basal cell carcinoma treatment market. Surgical excision is the most widely utilized treatment for basal cell carcinoma. The surgeon removes the malignant tumor together with a margin of good skin during this surgery. To ensure no cancer cells are present, the surplus is examined using a microscope. For basal cell carcinomas that are less prone to recur, such as those that develop on the chest, back, hands, and feet, excision may be advised.
Due to its lowest possible recurrence rates, highest possible cure rates, and best cosmetic outcomes among all treatment approaches for basal cell carcinoma, and surgical excision has proven to be more effective, leading to its high demand. Surgical removal with a 2-3-mm excision margin is an appropriate treatment with a 99% removal success rate for well-defined, primary-pigmented BCC.
The most popular kinds of skin cancer, basal cell carcinomas (BCCs) and squamous cell carcinomas (SCCs), are frequently treated with Mohs surgery. The process, known as Mohs micrographic surgery, is carried out in phases while the patient waits and includes lab testing. All malignant cells can be removed while sparing healthy tissue and leaving the lowest scar feasible to maximize the chance of curing cancer. Out of all available treatments, Mohs micrographic surgery has the highest success rate in curing basal cell and squamous cell skin malignancies. The cure rate for basal cell carcinoma is up to 99% for newly diagnosed patients and up to 94% for recurring cases. Over the next few, it is anticipated that surgical excision, followed by Mohs micrographic, will continue to dominate, reiterating the surgical segment's predominance.
Geographical Analysis
North America holds the largest market share in the global Basal Cell Carcinoma Treatment market.
North America dominates the global basal cell carcinoma treatment market primarily due to its large population, excellent medical infrastructure, and high-income levels. North America is anticipated to dominate the basal cell carcinoma treatment market throughout the forecast period. This is because of the rising incidence of the elderly population, increased knowledge of cutting-edge treatments, a favorable reimbursement environment, and the high frequency of basal cell carcinoma in this area.
According to the Centers for Disease Control and Prevention (CDC), there will be 3 to 4 million cases of non-melanoma skin cancer in the United States in 2020. This contributes to a larger patient base that needs the treatment. More individuals need medicine due to the rising prevalence of advanced basal cell carcinoma and Squamous cell carcinoma instances. Additionally, the region's growth is fueled by an increase in the number of new pharmaceuticals in the U.S. receiving regulatory approval.
For instance, in February 2021, As the first immunotherapy for patients with advanced basal cell carcinoma (BCC) who have not previously received a hedgehog pathway inhibitor (HHI) or for whom an HHI is not appropriate, the PD-1 inhibitor Libtayo (cemiplimab-rwlc) got FDA approval. Patients with locally advanced BCC received full approval, whereas those with metastatic BCC received accelerated approval. Additionally, the fact that Genetech and AiViva Biopharma International are conducting clinical trials to create novel therapeutics for basal cell carcinoma is likely to lead to an increase in the number of new product launches in the near term, which is also anticipated to fuel market growth.
Competitive Landscape
The Basal Cell Carcinoma Treatment market is moderately competitive with local and global companies’ presence Sun Pharmaceuticals Ltd., Merck & Co., Inc., Valeant Pharmaceuticals International, Inc., Regeneron Pharmaceuticals Inc, Hoffmann-La Roche Ltd., Mylan N.V., Perrigo Company, Strides Arcolab Ltd, AiViva Bio Pharma, Inc and Allergan Inc
The key players are adopting various growth strategies such as product launches, mergers & acquisitions, partnerships, and collaborations, contributing to the market’s growth. For instance, in December 2022, in a Phase I/II study to assess the safety and effectiveness of MW005 in the treatment of low-risk basal cell carcinoma, MediWound Ltd, a fully integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair and regeneration, today reported encouraging results (BCC).
Sun Pharmaceutical Industries, Inc.
Overview: An extensive selection of pharmaceutical formulations, including branded generics and generic medications, are offered by Sun Pharmaceutical Industries Ltd. (Sun Pharma), a speciality pharmaceutical company. Products for the treatment of psychiatric, neurological, nephrological, gastroenterological, orthopedic, and ophthalmologic diseases and disorders, as well as cardiac problems, are part of the company's portfolio.
Product Portfolio:
ODOMZO: It is a (sonidegib) is a prescription medicine used to treat adults with a type of skin cancer, called basal cell carcinoma, that has come back following surgery or radiation or that cannot be treated with surgery or radiation..
The global Basal Cell Carcinoma Treatment market report would provide access to approx.: 45+market data table, 40+figures and 200 (approximate) pages.